Phase 1a/b study assesses safety and pharmacokinetics of SAT-3247 in healthy volunteers and adults with Duchenne muscular dystrophy, indicating potential therapeutic benefits.
To assess safety, tolerability, pharmacokinetics (PK), and exploratory pharmacodynamics (PD) of SAT-3247 in a first-in-human phase 1a/1b study
No takes yet. Share an insight, caveat, or question.
Farwell et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: